Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Official Stresses "Flexibility" On Speeding Approval Of Drugs That Truly Stand Out

This article was originally published in The Pink Sheet Daily

Executive Summary

Four-year study of cancer drugs shows tyrosine kinase inhibitors commonly get cleared based on Phase II data in both accelerated and regular approvals. Emerging new classes could find faster paths.

You may also be interested in...



Halaven Survival Data Was Gold-Standard Lining In Forced Shift From Accelerated To Full Approval

Eisai’s development plan for Halaven was derailed by FDA’s approval of Ixempra in the same metastatic breast cancer indication, precluding the planned accelerated approval filing and redirecting the sponsor to a full approval track, but it also meant eribulin received the first approval in its highly refractory patient population ever to be based on overall survival data.

Halaven Survival Data Was Gold-Standard Lining In Forced Shift From Accelerated To Full Approval

Eisai’s development plan for Halaven was derailed by FDA’s approval of Ixempra in the same metastatic breast cancer indication, precluding the planned accelerated approval filing and redirecting the sponsor to a full approval track, but it also meant eribulin received the first approval in its highly refractory patient population ever to be based on overall survival data.

Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model

In an era in which biotechs struggle to get financing and Big Pharma is hungry for new drugs but typically favors deals that delay rewards, Plexxikon Inc. appears to have been dealt a top R&D hand and played its cards exceedingly well. Its strategy has culminated in one of the priciest private buyouts in recent history, its $805 million up-front acquisition by Japan’s Daiichi Sankyo Co. Ltd.

Related Content

Topics

UsernamePublicRestriction

Register

PS071366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel